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Edited by Ned ManteiAbstract Human bone mesenchymal stem cells (hMSCs) can
diﬀerentiate into endothelial cells (ECs), so we aimed to investi-
gate whether hMSCs could also diﬀerentiate into a speciﬁc arte-
rial or venous ECs. hMSCs were induced to diﬀerentiate into
ECs using vascular endothelial growth factor (VEGF). Low
VEGF concentration (50 ng/ml) upregulated the venous marker
gene EphB4, however high concentration (100 ng/ml) upregu-
lated the arterial marker genes ephrinB2, Dll4 and Notch4,
and downregulated the venous marker genes EphB4 and
COUP-TFll. This VEGF dose-dependent induction was largely
blocked by inhibition of the Notch pathway in hMSCs treated
with c-secretase inhibitor. Therefore, diﬀerentiation of hMSCs
into arterial- or venous-speciﬁc ECs depends on VEGF and is
regulated by the Notch pathway.
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Veins1. Introduction
Blood vessels consist of two cell types, endothelial cells
(ECs) and mural cells (vascular smooth muscle cells and peri-
cytes) that provide a wide variety of vascular diversity. EC
diversity is a main determinant of the vascular diversity. Re-
cently, speciﬁc markers for arteries and veins were discovered,
which labeled ECs from early development stages onwards, be-
fore the onset of blood ﬂow. A transmembrane ligand, Ephrin-
B2, and its receptor, the tyrosine kinase EphB4, were the ﬁrst
reported molecular markers for arterial and venous ECs,
respectively [1,2]. During the last several years, additionalAbbreviations: hMSCs, human bone mesenchymal stem cells; MSCs,
mesenchymal stem cells; ECs, endothelial cells; VEGF, vascular
endothelial growth factor; vWF, von Willebrand factor
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been identiﬁed. For arterial ECs, ephrinB1, Hey2, Jagged-1
and -2, neuropilin 1, and members of the Notch pathway ap-
pear to play critical roles [3]. Other molecules such as
COUP-TFll or neuropilin-2 are speciﬁcally expressed in the ve-
nous system [4].
Recently, many stem-cell types, including embryonic stem
cells [5,6], AC133+ endothelial progenitor cells, and multipo-
tent adult progenitor cells, have been found to diﬀerentiate
into arterial and venous ECs [7]. The Notch signaling pathway
has been considered important in regulating arterial–venous
cell speciﬁcation; loss of Notch or gridlock, a downstream tar-
get gene of Notch, led to a loss of Ephrin-B2 expression in
arteries in zebraﬁsh [8,9]. In addition, vascular endothelial
growth factor (VEGF) acts upstream of the Notch pathway
to determine arterial EC identity [9,10].
Recent studies have shown that mesenchymal stem cells
(MSCs) derived from human bone mesenchymal stem cells
(hMSCs) could be induced to diﬀerentiate into endothelial-like
cells [11–13]. Umbilical cord blood-derived and amniotic mem-
brane-derived hMSCs were also found to diﬀerentiate into ECs
in vitro and in vivo [14,15]. However, a precise analysis of the
arterial–venous speciﬁcation and the molecular mechanism in
hMSC diﬀerentiation into endothelial-like cells remains un-
known.
We aimed to investigate the mechanism by which VEGF in-
duces in hMSCs an arterial or venous fate in endothelial-like
cells and the role of Notch signaling in the process. Inhibition
of Notch signaling was found to attenuate VEGF-induced arte-
rial speciﬁcation in ECs and therefore promote venous identity.2. Materials and methods
2.1. Isolation and culture of hMSCs
Bone marrow was obtained from the sternum of children (age 6
months to 12 years) who were undergoing congenital heart disease sur-
gery, after approval by the ethics committee at Fu Wai Hospital. In-
formed consent was obtained from a parent of each donor, and the
study protocol conformed to the ethical guidelines of the 1975 Decla-
ration of Helsinki. Bone marrow aspirates of 3–5 ml were placed in a
tube containing 5 ml of phosphate-buﬀered saline (PBS) and 1250 ll
heparin. The marrow sample was loaded onto an equal volume of
1.073 g/ml Histopaque solution (Sigma–Aldrich) and centrifuged atation of European Biochemical Societies.
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lected and washed twice in PBS. The cells were seeded into 75 cm2
ﬂasks containing Iscoves modiﬁed Dulbeccos medium (IMDM) sup-
plemented with 10% fetal bovine serum (FBS) (Gibco Grand Island,
NY), penicillin (100 lg/ml), and streptomycin (100 lg/ml) and incu-
bated at 37 C in 5% CO2 and 95% humidity. After 3 days of culture,
adherent cells were allowed to continue to culture in medium that was
changed every 3 days. After 10–14 days of primary cultivation, the
adherent cells were 80–90% conﬂuent as visualized by phase contrast
microscope (Olympus IX70, Japan). Cells were dissociated with use
of 0.25% trypsin and 1 mM EDTA, replated in T-25 ﬂasks at
104 cells/cm2 and grown to near conﬂuence for passaging. hMSCs were
used at ﬁrst passage for all experiments. To inhibit Notch signaling, c-
secretase inhibitor (L-685,458; Bachem King of Prussia, PA) was
added at a concentration of 1 lM [16].
2.2. Diﬀerentiation of hMSCs into ECs
Human MSCs were plated at 2 · 104 cm2 in endothelial diﬀerenti-
ation medium containing Iscoves modiﬁed Dulbeccos medium
(IMDM), 50 or 100 ng/ml VEGF (R&D Systems, Minneapolis, MN)
and 5% FBS. The medium was changed every 2–3 days.
2.3. Flow cytometry
Human MSCs were trypsinized, incubated and stained with mouse
anti-human antibody for 30 min at room temperature, then rinsed
twice with PBS. The cells were resuspended in 500 ll of PBS after cen-
trifugation at 900 · g, then analyzed by use of a ﬂow cytometer (Bec-
ton–Dickinson, Franklin Lakes, NJ). About 5 · 105 cells/100 ll were
labeled with primary antibodies against CD14-PE, CD34-PE, CD45-
PE, CD90-PE, CD105-PE, and CD73-FITC (Becton–Dickinson).
Mouse IgG1-FITC and IgG1-PE (Becton–Dickinson) were used as iso-
type controls.Table 1
The oligonucleotide primer pairs used in this study
mRNA (GenBank accession number)
vWF (NM_000552) Sense
Antisense
KDR (NM_002019) Sense
Antisense
Flt-1 (NM_002019) Sense
Antisense
Tie-2 (NM_000459) Sense
Antisense
ephrinB2 (NM_004093) Sense
Antisense
ephrinB1 (NM_004429) Sense
Antisense
Dll4 (NM_019074) Sense
Antisense
Notch4 (NM_004557) Sense
Antisense
Hey2 (NM_012259) Sense
Antisense
EphB4 (NM_004444) Sense
Antisense
COUP-TFII (NM_021005) Sense
Antisense
GAPDH (NM_002046) Sense
Antisense2.4. Immunocytochemistry
Cells underwent staining for von Willebrand factor (vWF; Dako,
Carpinteria, CA), KDR, Flt-1, Tie-1, Tie-2, Ephrin-B2, Ephrin-B1,
and EphB4 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) after
ﬁxing with 4% paraformaldehyde for 15 min at room temperature
and washing with PBS three times. Cells were incubated in 0.1% Tri-
ton-100 for 30 min and blocked in 1% BSA for 20 min, rinsed, and
incubated with primary antibody overnight at 4 C. After incubation,
cells were washed with PBS three times. Secondary antibody was ap-
plied for 30 min at room temperature. After a wash with PBS, 3,3 0-
diaminobenzidine tetrahydrochloride (DAB) was applied to coverslips.
The color reaction was stopped by immersing the coverslips in distilled
water; coverslips were stained brieﬂy with hematoxylin, then dehy-
drated with alcohol and immersed in xylene. Negative control samples
were incubated in PBS without the primary antibodies. For immuno-
ﬂuorescent staining, secondary antibodies were coupled to FITC or
TRITC (Sigma–Aldrich, USA) and cells were stained with 4 0,6-diami-
dino-2-phenylindole (DAPI) for 10 min at room temperature. Images
were acquired by use of a microscope and a digital charge-coupled de-
vice camera (BX61; Olympus, Tokyo, Japan). Morphometric analyses
were performed using Image Pro-Plus software (version 5.1, Media
Cybernetics, Maryland, USA). To quantify the percentage of cultured
cells expressing arterial or venous markers, the number of positive cells
in ﬁve randomly selected ﬁelds was scored and divided by the total
number of cells.
2.5. Preparation of RNA and quantitative RT-PCR (qRT-PCR)
Total RNA was extracted by use of Trizol reagent (Invitrogen)
according to the manufacturers instructions and quantiﬁed by spectro-
photometry (Eppendorf AG Hamburg, Germany). cDNA was gener-
ated from 2 lg total RNA by use of M-MLV reverse transcriptase
(Promega) and oligo(dT) 15 primer. PCR ampliﬁcation was performedSequence
AGCCCATTTGCTGAGCCTTG
CCTGGCACCATGCATTTCTG
TCCTGTATGGAGGAGGAGGA
CGGCTCTTTCGCTTACTGTT
GGACTGACAGCAAACCCAAG
CAGCCCCGACTCCTTACTTT
TGCCCAGATATTGGTGTCCT
CTCATAAAGCGTGGTATTCACGTA
CTCCTCAACTGTGCCAAACCA
GGTTATCCAGGCCCTCCAAA
GTTCTCGACCCCAACGTGTT
CAGGCTTCCATTGGATGTTGA
CAGTGGGCAGCGAAGCTACA
ACAGGCAGTGGTAGCCATCCTC
GCCGATAAAGATGCCCAGGA
ATCCCAGTGGTTACGTTGGTGAG
TTCAAGGCAGCTCGGTAACTGAC
CATACTGATGCACTGCTGGATGG
GATGCCTGGAGTTACGGGATTG
TCCAGCATGAGCTGGTGGAG
TGGTTCCAAACCAGTTTATTCTGTG
AAGTGCGTTTCCATCATCTTTGAG
GCACCGTCAAGGCTGAGAAC
TGGTGAAGACGCCAGTGGA
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(5 lM)of each primer and 12.5 ll of the 2· Power SYBR Green
PCR Master Mix (Applied Biosystems, Foster City, CA). The real-
time PCR conditions were an initial denaturation step of 10 min at
95 C, followed by 40 cycles of 95 C for 15 s, and 64 C for 1 min.
Melting curve analysis involved use of ABI PRISM 7300 SDS (Applied
Biosystems). Fluorescent signals were normalized to that of GAPDH,
and the threshold cycle (Ct) was set within the exponential phase of the
PCR. The relative gene expression was calculated by comparing cycle
times for each target PCR. The target PCR Ct values were normalized
by subtracting the GAPDH Ct value, which was given as the DCt va-
lue. The relative expression level between treatments was then calcu-
lated using the following equation: relative gene expression = 2(DCt
sample  DCt control) [17]. Results are presented as fold increase in
gene expression in diﬀerentiated cells compared with that in undiﬀeren-
tiated cells. Primers used for real-time PCR are shown in Table 1.
2.6. In vitro EC functional tests
2.6.1. Incorporation of Dil-ac-LDL. To observe the uptake of 1,1 0-
dioctadecyl-1-3,3,3,3-tetramethyl-indo-carbocyanine perchlorate con-
jugated to acetylated LDL (Dil-ac-LDL) (Biomedical Technologies,
Stoughton, MA), diﬀerentiated hMSCs were seeded onto T-25-cm2
ﬂasks. The medium was replaced by fresh medium with 10 lg/ml Dil-
ac-LDL. After incubation for 4 h at 37 C, cells were washed several
times with probe-free media and observed by ﬂuorescence microscopy.
2.6.2. In vitro angiogenesis. Analysis of tubular structure formation
involved use of the in vitro angiogenesis kit (ECM625) according to
the manufacturers instructions (Chemincon, Temecula, CA, USA).
An amount of 50 ll of Matrigel was applied to one well of a 96-well
plate and incubated for 1 h at 37 C. Cells were trypsinized, and
5 · 103 cells were suspended in 100 ll IMDM containing 50 ng/ml
VEGF, plated onto the gel matrix and incubated at 37 C. After 4–
24-h incubation, the formation of a cord- or tube-like network was
examined and recorded by phase-contrast microscopy.Fig. 1. Human mesenchymal stem cells (hMSCs) in primary culture. (A) A
proliferate to 80–90% conﬂuence after 10–14 days culture. (C) Fluorescence-a
staining proﬁle (red line) versus speciﬁc antibody staining proﬁle (green line2.7. In vivo angiogenesis
Ten-week-old male nude mice (BALB/c-nu/nu, 4–5 weeks of age)
were used in this experiment. All animals received humane care,
and animal protocols complied with the Guide for the Care and
Use of Laboratory Animals prepared by the Institutes of Laboratory
Animal Resources, National Research Council, and published by the
National Academy Press, revised 1996 (NIH publication No. 85-
23).The mice were anesthetized with use of 1% pentobarbital
(80 mg/kg, given intraperitoneally) and injected subcutaneously in
the back with 300 ll Matrigel containing 100 ng/ml VEGF and
hMSCs or VEGF and no cells. The injected cells were pre-labeled
with 4 0,6-diamidino-2-phenylindole (DAPI) as described [18]. Two
weeks later, all mice were sacriﬁced, and Matrigel plugs were re-
moved and processed for OCT embedding. Tissue sections were
immunostained for human-speciﬁc vWF, ephrinB2, EphB4 and
mouse-speciﬁc CD31 and viewed by ﬂuorescence microscopy. Blood
vessel density was determined for ﬁve slices and ﬁve diﬀerent posi-
tions per slice after staining for CD31. The results are expressed as
number of vessels per 0.25 mm2.3. Results
3.1. Cultivation and determination of hMSCs
The hMSCs were spindle shaped, attached to the culture dish
tightly after 3–4 days primary passage culture, proliferated in
IMDM (Fig. 1A), and maintained similar morphology with
passages (Fig. 1B). Surface protein expression of conﬂuent
hMSCs at passages 1–3 examined by ﬂow cytometry revealed
an immunophenotypical proﬁle [19]. hMSCs displayed no
expression of hematopoietic markers CD14, CD34 anddherent spindle-shaped hMSCs after 4–6 days of culture. (B) hMSCs
ctivated cell sorting analysis of hMSCs. Plots show isotype control IgG
). Magniﬁcations 40· (A and B).
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CD90, CD105, CD73 (Fig. 1C).
3.2. VEGF induces hMSCs to diﬀerentiate into functional ECs
Conﬂuent hMSCs treated with VEGF (50 ng/ml) exhibited
no discernable morphologic change until the end of the third
week. Afer 14 days of exposure to 50 ng/ml, most hMSCs ex-
pressed VEGF receptors 1 (79 ± 4%) and 2 (87 ± 5%) (Flt-1
and KDR, respectively), angiopoietin receptors Tie-1
(85 ± 8%) and Tie-2 (83 ± 6%), and vWF (65 ± 4%), which
suggested diﬀerentiation to ECs (Fig. 2A–E). ECs were shown
to be functional by acetylated LDL uptake (97 ± 3%) (Fig.
2F) and had tube-forming potential (Fig. 2G). As a negative
control, about (23 ± 2%) cells among undiﬀerentiated hMSCs
took up red ﬂuorescence. The expression of vWF mRNA was
remarkably enhanced in hMSC-derived ECs (Fig. 2H). With
increased VEGF dosage (100 ng/ml), the expression of the
ECs markers KDR, Flt-1, Tie-2, and vWF was upregulated
but not signiﬁcantly (Fig. 2I).
3.3. VEGF controls arterial–venous diﬀerentiation of hMSCs
VEGF has been shown to determine arterial cell fate, with
exogenous expression causing ectopic expression of the arterial
marker ephrinB2 [9]. To study whether VEGF could induce
arterial cell diﬀerentiation from hMSCs in vitro, we investi-
gated arterial–venous diversity in hMSC-derived ECs by
immunocytochemistry and/or qRT-PCR. Low transcript levelsFig. 2. Human MSCs diﬀerentiate into functional ECs. After 2 weeks of di
KDR (A), Flt-1 (B), Tie-1 (C), Tie-2 (D), and vWF (E). Functionality of hM
and form a tube-like network in Matrigel after 24 h (G). (H) Quantitative
presence of VEGF (50 ng/ml). With increased VEGF dosage (100 ng/ml), t
upregulated but not signiﬁcantly (I). Results are mean (±S.D.) of three inde
day 0. Magniﬁcation 400·. Scale bars: 50 lm (A–E).of the arterial markers ephrinB2, Dll4 and Notch4 and the ve-
nous markers EphB4 and COUP-TFII were detected in
hMSCs before diﬀerentiation. With VEGF treatment (50 ng/
ml), ECs showed expression of the venous marker EphB4
but little of the arterial marker ephrinB2 on immunostaining
(Fig. 3A). With increased VEGF dosage (100 ng/ml), the
expression of the arterial markers ephrinB2 increased and
the venous EphB4 decreased at day 14 (Fig. 3B). Meanwhile,
the mRNA expression of the arterial genes Ephrin-B2, Dll4,
and Notch4 was strongly upregulated in ECs (Fig. 3C). In con-
trast, the venous genes EphB4 and COUP-TFII were downreg-
ulated as compared with their level at 50 ng/ml VEGF (Fig.
3C). Thus, arterial speciﬁcation in hMSC-derived ECs depends
on VEGF dosage.
3.4. Inhibition of Notch signaling attenuates arterial EC
diﬀerentiation of hMSCs
The underlying arterial–venous speciﬁcation mechanisms in
zebraﬁsh were demonstrated to be a regulatory signaling
cascade of sonic hedgehog–VEGF–Notch–EphB2 [20]. We
prevented Notch signaling with the c-secretase inhibitor L-
685,458 and found signiﬁcantly decreased expression of the
arterial markers Dll4 (P < 0.05), Hey2, and ephrinB2
(P < 0.01) but not ephrinB1 (P > 0.05) (Fig. 4). In contrast,
the venous marker COUP-TFII was signiﬁcantly increased in
expression (P < 0.01) and that of EphB4 slightly increased
but not signiﬁcantly.ﬀerentiation, most hMSCs stained positive for EC markers, including
SC-derived ECs shown by their ability to take up acetylated LDL (F)
expression of vWF upregulated after 2 weeks (2) and 3 weeks (3) in
he expression of the ECs markers KDR, Flt-1, Tie-2, and vWF was
pendent experiments performed in triplicate. *P < 0.01 compared with
Fig. 3. Arterial–venous diﬀerentiation of hMSC-ECs depends on
VEGF dose A and B. Double immunostaining of induced hMSC-ECs
with an arterial marker ephrinB2 and venous marker EphB4 in various
conditions. Upper panels, EphB4 (green) and DAPI (blue). Lower
panels, ephrinB2 (red) and DAPI (blue). (A) With 50 ng/ml VEGF,
hMSC-derived ECs showed few ephrinB2+-stained cells (11 ± 2%) but
many EphB4+-stained cells (65 ± 4%). (B) With 100 ng/ml VEGF,
hMSC-derived ECs showed increased positive staining for arterial
marker ephrinB2 (66 ± 5%) and decreased venous marker EphB4
(21 ± 3%). Magniﬁcation 400·. Scale bars: 50 lm (A–B). (C) mRNA
expression of arterial and venous genes in hMSC-derived ECs with 50
and 100 ng/ml VEGF at day 14. The mRNA levels in all panels are
expressed as fold increase compared with day 0 and were normalized
using GAPDH as housekeeping gene. Results are mean ± S.D. of three
independent experiments. *P < 0.01.
Fig. 4. Inhibition of Notch signaling attenuates arterial diﬀerentiation
in hMSC-derived ECs. Arterial and venous genes were analyzed by
quantitative RT-PCR with VEGF (100 ng/ml) with or without c-
secretase inhibitor. Notch blocking reduced expression of arterial EC
markers Hey2, Dll4, and ephrinB2, but not ephrinB1; meanwhile,
expression of venous markers COUP-TPII and EphB4 was increased.
Results are mean ± S.D. of three independent samples. *P < 0.05;
**P < 0.01.
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venous speciﬁcation
To investigate whether diﬀerentiated hMSCs can promote
arterial–venous endothelium formation in vivo, we injected
0.5 · 106 undiﬀerentiated DAPI-labeled hMSCs in Matrigel
containing 100 ng/ml VEGF onto the backs of nude mice;
VEGF alone without hMSCs served as control. Matrigel plugs
with hMSCs recovered for observation of the formation of
functional vessels 14 days later showed many new blood ves-
sels as compared with few blood vessels in controls (Fig. 5A
and B). Fluorescent-labeled hMSCs were observed on tissue
sections, which indicated that implanted cells persisted in
Matrigel plugs (Fig. 5C). Most implanted cells expressed hu-
man-speciﬁc vWF as well as ephrinB2 or EphB4, which indi-
cated their arterial–venous EC identity (Fig. 5D–F). Using
mouse-speciﬁc CD31 antibodies we stained blood vessels in
Matrigel plugs to show that the vascular structure were ofmouse origin (Fig. 5G and H). We quantiﬁed blood vessel den-
sity in Matrigel plugs by counting CD31-positive vessels; aver-
age vessels density was 13 ± 1.5 and 4.6 ± 1.1 vessels per
0.25 mm2 in plugs seeded with or without hMSCs, respectively
(Fig. 5G and H). However, we observed that the DAPI-labeled
hMSC surrounded the lumen and we did not ﬁnd any evidence
for integration of hMSC-derived ECs into the endothelium of
host growing vessels (Fig. 5G). So, the hMSCs-derived ECs
contributed to growing of host vessels and did not signiﬁcantly
contribute to the structure of a vessel-like lumen.4. Discussion
Arterial or venous EC speciﬁcation is highlighted in vascular
development. Understanding the molecular and cellular mech-
anisms of EC diversiﬁcation would contribute to the explora-
tion of vascular regeneration and provide materials for cell
and gene therapy and novel drugs for regenerative medicine.
At present, arterial–venous endothelial diﬀerentiation of stem
cells is described mainly in the context of the study of embry-
onic stem and multipotent adult progenitor cells [5–7]. hMSCs
have been considered a promising source of stem cell-based
regenerative medicine because of the few ethical and legal con-
cerns surrounding their use, their convenient isolation and
powerful ex vivo expansion, and long-term cryopreservation.
To date, little evidence of hMSCs inducing the diﬀerentiation
of arterial and venous ECs has been reported. In the present
study, we describe a protocol to derive ECs with arterial and
venous features from hMSCs. These cells display speciﬁc arte-
rial and venous gene expression as well as functional angiogen-
esis in vitro, however, in vivo they only adopted an arterial–
venous EC phenotype and did not signiﬁcantly contribute to
the structure of a vessel-like lumen.
VEGF is necessary for endothelial development in vivo,
and targeted inactivation of VEGF alleles produces a tight
Fig. 5. In vivo arterial and venous diﬀerentiation of hMSC-derived ECs. In vivo image of a mouse Matrigel plug containing VEGF with (A) or
without hMSCs (B). Immunohistochemical staining of cryosection of Matrigel plug showing DAPI-labeled hMSCs (C), human-speciﬁc vWF (D),
venous marker EphB4 (E), and arterial marker ephrinB2 (F). Mouse-speciﬁc CD31 indicating the blood vessels in Matrigel plugs were host derived
(G and H). Blood vessel density was higher in plugs containing VEGF plus hMSCs (G) compared to VEGF alone (H). The DAPI-labeled hMSCs
surrounded the vessel lumen and were not integrated into the endothelium of vessels (G). Arrows indicate the endothelium of vessels (G and H).
Magniﬁcation 100· (C); 400· (D–H). Scale bars: 50 lm (D–H); 200 lm (C).
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[21]. In our in vitro study, diﬀerentiation of ECs from hMSCs
was dependent on dosage of VEGF. With low concentration
of VEGF (50 ng/ml), arterial-speciﬁc genes were expressed at
very low levels, but venous-speciﬁc genes showed high expres-
sion. Increasing the level of VEGF (to 100 ng/ml) resulted in
strong upregulation of arterial markers but downregulated ve-nous markers COUP-TFII and EphB4. Thus, graded VEGF
signaling could promote arterial endothelial induction.
Mukouyama and coworkers demonstrated that small-diameter
arterioles but not venules preferentially aligned with sensory
nerves in the embryonic skin of mutant mice [22]. High VEGF
concentration secreted by the neurons and/or Schwann cells is
required for arteriogenesis of small-diameter arteries [22].
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nascent ECs are plastic and their identity can be changed by lo-
cal environmental cues [23]. Our results also show that hMSC-
derived ECs remain plastic with regard to arterial–venous dif-
ferentiation. Venous-enriched genes are expressed at low levels
even after arterial fate speciﬁcation [24]. As well, venous gene
markers are upregulated with low concentrations of VEGF in
embryonic stem cells [5]. These reports are compatible with
our results showing that venous EC diﬀerentiation may be con-
sidered the default pathway of EC diﬀerentiation [25].
VEGF and the Notch pathway are strongly related in endo-
thelial development. VEGF regulates arterial cell fate determi-
nation through the Notch pathway [9,26,27]. Our inhibition of
Notch signaling decreased the expression of arterial markers
Hey2, Dll4 and ephrinB2 but not ephrinB1. Furthermore,
COUP-TFII expression was signiﬁcantly increased. VEGF
induction of arterial genes was not completely abrogated
through inhibition of the Notch pathway, which indicates
the existence of additional Notch-independent pathways in
arterial diﬀerentiation. In embryonic stem cells, VEGF treat-
ment alone with serum is suﬃcient for induction of venous
ECs but not arterial ECs [6]. Stimulation of the cyclic adeno-
sine monophosphate (cAMP) pathway by adrenomedullin in-
duced ephrinB2+ arterial ECs [6]. Other factors such as
TGF-b, angiopoietins, or COUP-TFII may play a role in arte-
rial–venous cell fate [28–30].
In agreement with our in vitro data, in vivo hMSCs were
capable of arterial–venous EC diﬀerentiation. Indeed, DAPI-
labeled hMSCs expressed the EC marker vWF, the arterial
marker EphrinB2 or the venous marker EphB4. In addition,
hMSC-derived ECs contributed to the formation of new host
blood vessels in vivo and surrounded the lumen of blood ves-
sels. Some studies have shown that injected MSCs are incorpo-
rated in new blood vessels [31], but we did not ﬁnd any
evidence of integration of hMSC-derived ECs into the endo-
thelium of host-growing vessels.
Together, our data show that VEGF is required for arterial–
venous EC diﬀerentiation of hMSCs and the eﬀect is dose
dependent. hMSC-derived ECs remain plastic in terms of arte-
rial–venous diﬀerentiation. High VEGF concentration led to
the expression of arterial marker genes, whereas low VEGF
concentration contributed to venous diﬀerentiation. After inhi-
bition of Notch signaling, this VEGF-induced arteriogenesis
was largely blocked, which resulted in a shift from arterial to
venous cell fate. Our study may be of importance for the de-
sign of EC-coated arterial grafts and autologous cell-based
therapies for ischemic diseases.
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